Intra-Cellular short report concerns ‘unwarranted,’ says RBC Capital

RBC Capital notes that the firm has been receiving questions regarding a short report that points to potential tolerability issues with Intra-Cellular’s Caplyta, but the firm believes the implications of any described tolerability issues are unlikely to be material to the long-term trajectory of the treatment and it continues to be a buyer of the shares. Most of the described reports "appear anecdotal" and represent only tolerability issues that may lead some patients to discontinue, as "with any drug," and do not point to any major safety concerns, said the firm, which has an Outperform rating and $75 price target on Intra-Cellular shares.